The poor association between HER2 amplification and HER2 overexpression in NSCLC, compared to breast cancer, is probably the reason for the low effectiveness of HER2-targeted therapies in NSCLC. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.